Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

SGN-10. Seattle Genetics.

¹Suzanne_Smith162@hotmail.com

Current Opinion in Investigational Drugs (London, England : 2000)

|November 23, 2001

Summary

This summary is machine-generated.

Seattle Genetics is developing SGN-10, a potent single-chain immunotoxin, for cancer treatment. This investigational therapy is more effective and easier to manufacture than previous compounds.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Neuro-ophthalmologic manifestations of cholangiocarcinoma: a case series.

Eye (London, England)·2017

Same author

Biodistribution and dosimetry of 195mPt-cisplatin in normal volunteers. Imaging agent for single photon emission computed tomography.

Nuklearmedizin. Nuclear medicine·2013

Same author

Imagine the imagery: opportunities and challenges.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2008

Same author

Radiometal complexes: characterization and relevant in vitro studies.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2008

Same author

Sarar technology for the application of Copper-64 in biology and materials science.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2008

Same author

Soil erosion and significance for carbon fluxes in a mountainous Mediterranean-climate watershed.

Ecological applications : a publication of the Ecological Society of America·2007

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

Area of Science:

Oncology
Immunotherapy
Drug Development

Background:

Seattle Genetics is developing SGN-10 (BR96-SCIT), a single-chain immunotoxin (SCIT), licensed from Bristol-Myers Squibb (BMS).
SGN-10 is a follow-up to SGN-15 (BR96-DOX), designed for improved efficacy and manufacturing efficiency.
BMS licensed the underlying single-chain antigen-binding protein (SCA-protein) technology from Enzon in 1993.

Purpose of the Study:

To evaluate SGN-10 as a monotherapy and in combination with Taxotere for cancer treatment.
To assess the potential of SGN-10 in ongoing phase I clinical trials.

Main Methods:

SGN-10 utilizes a potent bacterial toxin, 250 times more effective than BR96-DOX and smaller in size for enhanced tumor penetration.
Development involves licensing agreements and progression through phase I clinical trials.

Related Experiment Videos

Main Results:

SGN-10 is currently undergoing phase I clinical trials.
The compound is designed to be more effective and cost-efficient to manufacture compared to its predecessor.

Conclusions:

SGN-10 represents a potentially improved immunotoxin therapy for cancer.
Further clinical evaluation is underway to establish its therapeutic value.